Lunit, a trailblazer in AI-driven diagnostics and cancer treatment,  announced significant strides in its European market presence through new supply contracts in France and Portugal. These agreements, with TeleDiag and the Portuguese League Against Cancer (LPCC), respectively, underscore Lunit's commitment to enhancing cancer detection accuracy with its advanced AI technologies.

TeleDiag Integration: A Leap in French Lung Disease Diagnosis

In France, Lunit's collaboration with TeleDiag, the nation's premier teleradiology network, introduces Lunit INSIGHT CXR, an AI solution adept at identifying 10 common lung abnormalities, including lung cancer. This initiative marks a pivotal advancement in incorporating AI into French healthcare, leveraging TeleDiag's extensive network of over 600 radiologists and more than 300 medical facilities to improve lung disease detection outcomes.

TeleDiag's choice of Lunit followed an exhaustive review of competing AI technologies, with Lunit's comprehensive diagnostic capabilities and robust performance sealing its selection.

Portuguese Cancer Detection Enhancement with Lunit INSIGHT MMG

Similarly, in Portugal, the LPCC's central region branch will employ Lunit INSIGHT MMG for mammography analysis. This FDA-cleared and CE-marked tool is set to revolutionize breast cancer detection for approximately 100,000 mammograms annually over the next three years.

The LPCC, an authoritative figure in Portugal's National Breast Cancer Screening Program since 1941, validated Lunit's technology using its screening data, confirming the solution's superior diagnostic accuracy.

Global Diagnostic Transformation

These partnerships, announced on the heels of new contracts in East and Southeast Asia, signal Lunit's global expansion and its vision to transform cancer diagnostics worldwide. "Our collaboration with TeleDiag and LPCC in Europe reflects our global mission to enhance patient outcomes through AI-powered diagnostics," stated Brandon Suh, Lunit's CEO. "We're dedicated to delivering our cutting-edge screening solutions to healthcare providers around the globe, ensuring widespread access to superior cancer detection."